District Court Rules DNA Analysis Claims Reciting Mathematical Algorithms Ineligible Under § 101

Oct 26, 2020

Reading Time : 3 min

The Cybergenetics patents at issue—U.S. Patent Nos. 8,898,021 and 9,708,642—describe a variation of a traditional method of identifying an individual based on a DNA sample. The traditional method uses “PCR (polymerase chain reaction) amplification” to transform the DNA sample into data that are unique to an individual and thus can be used to identify that individual. The method is not useful, however, when the sample contains DNA from multiple sources because the transformed data are “mixed” and do not correspond to one individual.

The patents address that problem by employing what they call “deconvolution”—a process that accounts for multiple individuals in a DNA sample by “calculating the variance of the DNA data produced by PCR amplification and accounting for that variance in subsequent probability calculations.” The probability calculations “predict the identity of an individual in the sample and calculate the likelihood that the prediction is correct.” In other words, the patented methods determine the likelihood that a given individual’s DNA is contained in a sample instead of merely identifying one individual.

Cybergenetics asserted several claims of these patents against the Institute of Environmental Science and Research, and NicheVision Inc., based on their alleged use of “deconvolution” technology. The court granted the defendants’ motion to dismiss after determining that the asserted claims fail both steps of the Alice framework.

Under step one, the court explained that the Cybergenetics claims “recite mathematical algorithms to produce a numerical output as the entirety of the method.” In particular, the claimed “deconvolution” process “describes the process of calculating a variance (a numerical result) and then accounting for that variance in subsequent statistical calculations (also numerical results).” The court further explained that the U.S. Supreme Court and Federal Circuit have repeatedly held that mathematical algorithms are examples of abstract ideas. It then found that the use of algorithms is “⁠[t]he only difference between” conventional methods and the claimed methods, further showing that the claims are “directed to” such abstract ideas.

The court rejected Cybergenetics’ argument that the asserted claims were akin to those analyzed in the Federal Circuit’s Thales, McRO and CardioNet cases in which claims survived Alice challenges despite reciting mathematical algorithms. The court explained that the mathematical algorithms in those cases “were used as part of a non-mathematical process” (emphasis added). For example, in Thales, a mathematical algorithm and its result were used “to track the position and orientation of [an] object.” In McRO, an algorithm was used to “generate a tangible product, namely a video of a 3-D character speaking [] recorded audio.” And in CardioNet, the claims improved the operation of a cardiac monitoring machine, albeit through the use of an algorithm. Unlike in those cases, “the numerical result” in the Cybergenetics claims is the claimed “improvement,” and the numerical result is not used for any “non-mathematical process.”

Under step two, the court explained that the Cybergenetics claims fail to recite an “inventive concept” because they do not recite any “elements other than the computation of mathematical algorithms and reporting the numerical results.” Specifically, some claims merely recite mathematical algorithms, some recite a generic computer that calculates the mathematical algorithms (or merely display the results of such calculations) and some recite the conventional step of using “PCR amplification” to transform a DNA sample into data. According to the court, all three categories of claims “capture patent-ineligible ideas.” 

The court rejected the argument that the “inventive concept” is a specific application of a mathematical technique to “computer-based DNA analysis” or to “probabilistic genotyping.” As the court explained, “[c]ourts have consistently rejected finding a claim provides an inventive concept simply because it is limited ‘to one field of use.’”

Practice Tip: After six years, courts continue to use Alice to dismiss patent claims directed to so-called “abstract ideas.” The Cybergenetics case demonstrates the fine line between claims that are directed to a mathematical algorithm—one of the few things the higher courts have specifically identified as an “abstract idea”—and claims that merely use them. When possible, patentees should draft claims (and specifications) in a way that emphasizes tangible improvements even when achieving such improvements requires using a mathematical algorithm. By the same token, defendants should consider attacking any patent claims that rely on a mathematical algorithm, and they should try to characterize that algorithm as the focus of the patent and the claims. The Cybergenetics case will certainly be one worth monitoring on appeal (if there is one) to see if the Federal Circuit agrees with the district court’s analysis.

Cybergenetics Corp. v. Institute of Environmental Science and Research, 5:19-cv-1197 (N.D. Ohio Sep. 29, 2020) (Lioi, J.)

Share This Insight

Previous Entries

IP Newsflash

December 9, 2025

The Federal Circuit recently denied a petition for a writ of mandamus that challenged the PTO Director’s reliance on “settled expectations” to discretionarily deny two inter partes review (IPR) petitions. In so doing, the court explained that, while it was not deciding whether the Director’s use of “settled expectations” was correct, the petitioner’s arguments about what factors the Director may consider when deciding whether to institute an IPR or post-grant review (PGR) are not generally reviewable and did not provide sufficient basis for mandamus review here.

...

Read More

IP Newsflash

December 5, 2025

District courts are split on whether a complaint can provide the required knowledge for post-suit indirect and willful infringement in that same lawsuit. Chief Judge Connolly in the District of Delaware recently confirmed that, consistent with his prior opinions, the complaint cannot serve as the basis for knowledge for either a claim of post-suit indirect infringement or a demand for willfulness-based enhanced damages in that lawsuit.

...

Read More

IP Newsflash

December 3, 2025

The Federal Circuit recently held that a patentee acted as its own lexicographer to define a claim term even though it did not explicitly define the term. Rather, because the patentee consistently and clearly used two terms interchangeably to describe the same structural feature and did so in all of the embodiments in which the feature appeared, the patentee impliedly gave the term its own, unique definition.

...

Read More

IP Newsflash

December 2, 2025

The Federal Circuit recently held an asserted patent was not entitled to its priority date because the priority application lacked written description support for the asserted claims. In so doing, the court explained that broad disclosures that do not provide reasonably specific support for narrower claims do not meet the written description requirement. The court also considered whether the inventor’s testimony showed they possessed the full scope of the claimed genus at the priority date or whether it was more likely the inventors first became aware of the claimed embodiments from public disclosures of the accused product.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.